Cargando…

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study

BACKGROUND: Hereditary Transthyretin Amyloidosis Polyneuropathy is a rare life-threatening neurologic disease that imposes considerable mortality and it is associated with progressive related disabilities. In this study, we aimed to assess the effect of the disease across health-related quality of l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inês, Mónica, Coelho, Teresa, Conceição, Isabel, Ferreira, Lara, de Carvalho, Mamede, Costa, João
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060628/ https://www.ncbi.nlm.nih.gov/pubmed/32143656 http://dx.doi.org/10.1186/s13023-020-1340-x

Ejemplares similares

Transthyretin familial amyloid polyneuropathy impact on health-related quality of life
por: Inês, Mónica, et al.
Publicado: (2015)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2022)

Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2020)

Corrigendum: Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2022)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
por: Skrahina, Volha, et al.
Publicado: (2021)

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
por: Carroll, Antonia, et al.
Publicado: (2022)

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
por: Cortese, Andrea, et al.
Publicado: (2017)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
por: Pedroto, Maria, et al.
Publicado: (2023)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
por: Obici, Laura, et al.
Publicado: (2023)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

Advances in the treatment of hereditary transthyretin amyloidosis: A review
por: Gertz, Morie A., et al.
Publicado: (2019)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR
por: Yarlas, Aaron, et al.
Publicado: (2021)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy
por: Gasparotti, Roberto, et al.
Publicado: (2023)

Burden of hereditary transthyretin amyloidosis on quality of life
por: Yarlas, Aaron, et al.
Publicado: (2019)

Gait Characterization and Analysis of Hereditary Amyloidosis Associated with Transthyretin Patients: A Case Series
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2022)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

Monitoring the Patient with Retinal Angiopathy Associated with Hereditary Transthyretin Amyloidosis: Current Perspectives
por: Marques, João Heitor, et al.
Publicado: (2022)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Screening for hereditary transthyretin amyloidosis in Bulgaria
por: Nakov, Radislav, et al.
Publicado: (2021)

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
por: Coelho, Teresa, et al.
Publicado: (2022)

Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study
por: Yarlas, Aaron, et al.
Publicado: (2021)

Accessibility to Occupational Therapy Services for Hereditary Transthyretin Amyloidosis
por: Gayà-Barroso, Aina, et al.
Publicado: (2022)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
por: Vegezzi, Elisa, et al.
Publicado: (2022)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
por: Yamaguchi, Hiroki, et al.
Publicado: (2022)

Hereditary Transthyretin Amyloidosis in Eight Chinese Families
por: Meng, Ling-Chao, et al.
Publicado: (2015)

Hereditary transthyretin amyloidosis: a case report
por: Lee, Angela, et al.
Publicado: (2022)

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020)

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis
por: Obici, Laura, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pemgmj3h6o3el8kthmev1gv746